Last day focused on Treatments.These are the main highlights.
Dr. Jarred Younger appeared in a video and talked about future PET/MRI studies looking for a cause for brain inflammation and try to identify activated microglia.
Also he will decode data from large longitudinal studies looking at inflammation markers and other things - lots of good data to try and define subsets.
And in Gulf War Illness and Fibromyalgia has treatment studies using botanicals and others to reduce pain and improve energy by addressing inflammation - at least three seems to be looking hopeful.
He said to expect lots of papers in 2019
And he is working on developing a new medication that will be better than low dose naltrexone to calm down microglia.
Dr. Davis talked about 3 drugs that move the "needle" and one metabolite very low in some severe patients.
1. Indoleproplonate is made in the gut. It seems severe patients may be low in the bacteria that produces this. Indoleproplonate is a neuro protective agent.
[Screenshot removed]
2. He has previously talked about Ativan correcting the nanoneedle signature (IIMEC13 June 2018). Since then they have seen the same reaction on the Seahorse ($120,000 instrument). They test with activated T-Cells which happen to express GABA receptors (possible mechanism of activation).
[Screenshot removed]
3. Lastly he announced two other drugs that correct the nanoneedle impedance signature when used with a patients blood. Copaxone and a new drug called SS31.
[Screenshot removed]
He summarised to say that they don't know why these drugs have the effect they do.
Of note is that Copaxone is an MS drug. Ron Davis has talked with MS experts and they agree that their MS patients match the diagnostic criteria for ME/CFS but insist their patients do not also have ME/CFS in addition to ME..................
EDIT : Screenshots removed as Emerge do not want people to share